Heart Failure in Kidney Transplant Recipients: Narrative Review of Risk Factors, Therapy, and Current Gaps in Management
Cardiology and Therapy · 2026-03 · 15 (1) · 1-23
DOI: 10.1007/s40119-026-00446-8 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cardiology and Therapy, online erschienen am 23.02.2026. Verfasst von Anukul Ghimire und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology and the Ajmera Transplant Centre, University Health Network, Toronto, ON, Canada. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 132 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Among kidney transplant recipients (KTR), cardiovascular disease remains the leading cause of mortality, with heart failure (HF) being especially common in this population. Risk factors for HF in KTR can be categorized as traditional (risks relevant to the general population) versus nontraditional (unique to kidney disease and transplantation). Despite the substantial burden of cardiovascular disease, KTR have been excluded from large clinical trials in cardiovascular medicine and from landmark studies looking at the kidney-protective effects of novel cardiorenal metabolic agents, including sodium-glucose cotransporter 2 inhibitors (SGLT2i). Thus, there is uncertainty about the safety and efficacy of the use of guideline directed medical therapy (GDMT) for HF in this population. Long-term optimal use of GDMT in KTR is limited by various barriers, including the risk of hyperkalemia from concomitant use of renin-angiotensin inhibitors and mineralocorticoid receptor antagonists, fears about genitourinary infections from SGLT2i, and lack of evidence for kidney-protective effects from GDMT agents among KTR. Overcoming these barriers will require a multifaceted approach that involves evidence generation to understand the efficacy and safety of GDMT among KTR, implementation-based strategies to increase uptake of GDMT, and development of multispecialty combined clinical care approaches to care for KTR with HF.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Nephrology and the Ajmera Transplant Centre, University Health Network, Toronto, ON, Canada.
- Division of Nephrology, Dalhousie University, Halifax, NS, Canada.
- Divisions of Transplant Medicine and Nephrology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.
- Division of Nephrology, Dalhousie University, Halifax, NS, Canada. Amanda.Vinson@nshealth.ca.
Zitieren
APA
Ghimire, A., Al-Zaneen, G., Michaud, J. B., Worthen, G., Rampersad, C., Singh, S. K. S., Lam, N. N., Kim, S. J., Tennankore, K. K., & Vinson, A. (2026). Heart Failure in Kidney Transplant Recipients: Narrative Review of Risk Factors, Therapy, and Current Gaps in Management. Cardiology and Therapy, 15(1), 1-23. https://doi.org/10.1007/s40119-026-00446-8
Vancouver
Ghimire A, Al-Zaneen G, Michaud JB, Worthen G, Rampersad C, Singh SKS, et al. Heart Failure in Kidney Transplant Recipients: Narrative Review of Risk Factors, Therapy, and Current Gaps in Management. Cardiology and Therapy. 2026;15(1):1-23. doi:10.1007/s40119-026-00446-8
BibTeX
@article{Ghimire2026,
author = {Ghimire, Anukul and Al-Zaneen, Gaeth and Michaud, Jacob B and Worthen, George and Rampersad, Christie and Singh, Sunita K S and Lam, Ngan N and Kim, S Joseph and Tennankore, Karthik K and Vinson, Amanda},
title = {Heart Failure in Kidney Transplant Recipients: Narrative Review of Risk Factors, Therapy, and Current Gaps in Management},
journal = {Cardiology and Therapy},
year = {2026},
volume = {15},
number = {1},
pages = {1--23},
doi = {10.1007/s40119-026-00446-8}
}
EUVIMED